Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Georgiops Tsironis, Konstantinos Koutsoukos, Konstantinos Athanasakis, Anna Tsiara, Kimon Tzannis, Margarita Gerolympou, Anastasios Visvikis, Georgios Oikonomopoulos, Alexandra Kollia, Efstathia Giannopoulou, Marialena Dimitra, Efthymios Kostouros, Athanasios Papatsoris, Athanasios Dellis, Konstantinos Stravodimos, Ioannis Varkarakis, Epaminontas Samantas, Gerasimos. Aravantinos, Nikolaos Kentepozidis, Christos Christodoulou, Vasiliki Bozionelou, Meletios Athanasios. Dimopoulos & Aristotle Bamias. (2019) Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece––the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). Expert Review of Pharmacoeconomics & Outcomes Research 19:4, pages 491-501.
Read now
Read now
Articles from other publishers (14)
Laurence Albigès, Carine Bellera, Sébastien Branchoux, Mickael Arnaud, Amandine Gouverneur, Sonia Néré, Anne-Françoise Gaudin, Isabelle Durand-Zaleski & Sylvie Négrier. (2023) Real-world treatment patterns and effectiveness of patients with advanced renal cell carcinoma: a nationwide observational study. Clinical Genitourinary Cancer.
Crossref
Crossref
Alessandra Buja, Giuseppe De Luca, Maura Gatti, Filippo Bonaldi, Mario Gardi, Alberto Bortolami, Matteo Sepulcri, Davide Bimbatti, Vincenzo Baldo, Manuela Scioni, Marco Maruzzo, Umberto Basso & Vittorina Zagonel. (2023) Estimated Direct Costs of Renal Cancer by Stage of Disease at Diagnosis and Phase of Its Management: A Whole-Disease Model. Clinical Genitourinary Cancer 21:4, pages e252-e260.
Crossref
Crossref
Alessandra Buja, Giuseppe De Luca, Maura Gatti, Claudia Cozzolino, Massimo Rugge, Manuel Zorzi, Mario Gardi, Matteo Sepulcri, Davide Bimbatti, Vincenzo Baldo, Marco Maruzzo, Umberto Basso & Vittorina Zagonel. (2022) Renal cell carcinoma: the population, real world, and cost-of-illness. BMC Urology 22:1.
Crossref
Crossref
Zhanchen Liao, Zhitao Fang, Siqi Gou, Yong Luo, Yiqi Liu, Zhun He, Xin Li, Yansong Peng, Zheng Fu, Dongjin Li, Haiyun Chen & Zhigang Luo. (2022) The role of diet in renal cell carcinoma incidence: an umbrella review of meta-analyses of observational studies. BMC Medicine 20:1.
Crossref
Crossref
Bernard Escudier, Marie de Zélicourt, Redha Bourouina, Camille Nevoret & Antoine Thiery-Vuillemin. (2022) Management and Health Resource Use of Patients With Metastatic Renal Cell Carcinoma treated With Systemic Therapy Over 2014-2017 in France: A National Real-World Study. Clinical Genitourinary Cancer 20:6, pages 533-542.
Crossref
Crossref
Thomas E HutsonFrank X LiuChristopher DieyiRuth KimStan KrulewiczVijay KasturiAbhijeet Bhanegaonkar. (2021) Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis. Journal of Managed Care & Specialty Pharmacy 27:9, pages 1171-1181.
Crossref
Crossref
Martin Bögemann, Aleksandra Zagorska, Divine Akumo, Laila El Hadad & Marc Pignot. (2020) Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany. Urologia Internationalis 104:11-12, pages 982-993.
Crossref
Crossref
Michael Moran, Dana Nickens, Katherine Adcock, Meg Bennetts, Natalie Charnley & Kate Fife. (2019) Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. Future Oncology 15:34, pages 3987-4001.
Crossref
Crossref
Andrea N. Burnett-Hartman, Natalia Udaltsova, Lawrence H. Kushi, Christine Neslund-Dudas, Alanna Kulchak Rahm, Pamala A. Pawloski, Douglas A. Corley, Sarah Knerr, Heather Spencer Feigelson, Jessica Ezzell Hunter, David C. Tabano, Mara M. Epstein, Stacey A. Honda, Monica Ter-Minassian, Julie A. Lynch & Christine Y. Lu. (2019) Clinical Molecular Marker Testing Data Capture to Promote Precision Medicine Research Within the Cancer Research Network. JCO Clinical Cancer Informatics:3, pages 1-10.
Crossref
Crossref
Michael Moran, Dana Nickens, Katherine Adcock, Meg Bennetts, Arial Desscan, Natalie Charnley & Kate Fife. (2019) Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data. Targeted Oncology 14:4, pages 405-416.
Crossref
Crossref
Huan Deng, Wenfeng Liu, Ting He, Zhengdong Hong, Fengming Yi, Yiping Wei & Wenxiong Zhang. (2019) Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology 9.
Crossref
Crossref
Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu & Ya-Chen Tina Shih. (2018) Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. PharmacoEconomics 37:3, pages 301-331.
Crossref
Crossref
Tiphaine Cholley, Antoine Thiery-Vuillemin, Samuel Limat, Marion Hugues, Fabien Calcagno, Guillaume Mouillet, Amélie Anota & Virginie Nerich. (2019) Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies. Clinical Genitourinary Cancer 17:1, pages e227-e234.
Crossref
Crossref
Peter J. Goebell, Michael Staehler, Lothar Müller, Arnd Nusch, Michael Scheffler, Annette Sauer, Ulla von Verschuer, Susanne Tech, Lisa Kruggel, Martina Jänicke & Norbert Marschner. (2018) Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry. Clinical Genitourinary Cancer 16:6, pages e1101-e1115.
Crossref
Crossref